News headlines about ArQule (NASDAQ:ARQL) have trended somewhat positive on Thursday, according to Accern. Accern scores the sentiment of media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. ArQule earned a coverage optimism score of 0.09 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 45.6620822145367 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the media headlines that may have impacted Accern’s scoring:
- ArQule (ARQL) Rating Lowered to Hold at Zacks Investment Research (americanbankingnews.com)
- Cytokinetics (CYTK) vs. ArQule (ARQL) Head-To-Head Comparison (americanbankingnews.com)
- A Look at Target Price and Valuation of Arqule Inc (ARQL) – ExpertGazette (expertgazette.com)
- ArQule, Inc. (ARQL) to achieve 10.00% EPS growth for next year – Wallstreet Investorplace (wallstreetinvestorplace.com)
- ArQule, Inc. (ARQL) receives consensus rating of 2.30 – Nasdaq Fortune (press release) (nasdaqfortune.com)
Shares of ArQule stock opened at $2.87 on Thursday. The firm has a market cap of $202.10, a P/E ratio of -7.36 and a beta of 1.43. The company has a current ratio of 4.98, a quick ratio of 4.98 and a debt-to-equity ratio of 1.03. ArQule has a 1 year low of $0.92 and a 1 year high of $2.94.
Several research firms have recently issued reports on ARQL. Zacks Investment Research lowered shares of ArQule from a “buy” rating to a “hold” rating in a report on Wednesday. ValuEngine upgraded shares of ArQule from a “sell” rating to a “hold” rating in a report on Thursday, March 15th. Roth Capital began coverage on shares of ArQule in a report on Thursday, February 22nd. They set a “buy” rating and a $5.00 target price for the company. B. Riley began coverage on shares of ArQule in a report on Friday, February 2nd. They set a “buy” rating and a $3.00 target price for the company. Finally, Needham & Company LLC upgraded shares of ArQule from a “hold” rating to a “buy” rating in a report on Thursday, December 14th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $3.50.
ArQule Company Profile
ArQule, Inc is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focuses on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of over four drug candidates, all of which are in targeted patient populations.
Receive News & Ratings for ArQule Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArQule and related companies with MarketBeat.com's FREE daily email newsletter.